ERK2, but Not ERK1, Mediates Acquired and “De novo” Resistance to Imatinib Mesylate: Implication for CML Therapy

Resistance to Imatinib Mesylate (IM) is a major problem in Chronic Myelogenous Leukaemia management. Most of the studies about resistance have focused on point mutations on BCR/ABL. However, other types of resistance that do not imply mutations in BCR/ABL have been also described. In the present rep...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Aceves-Luquero, Clara I., Agarwal, Anupriya, Callejas-Valera, Juan L., Arias-González, Laura, Esparís-Ogando, Azucena, del Peso Ovalle, Luis, Bellón-Echeverria, Itxaso, de la Cruz-Morcillo, Miguel A., Galán Moya, Eva M., Gimeno, Inmaculada Moreno, Gómez, Juan C., Deininger, Michael W., Pandiella, Atanasio, Prieto, Ricardo Sánchez
Формат: Artigo
Язык:Inglês
Опубликовано: Public Library of Science 2009
Предметы:
Research Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2699476/
https://ncbi.nlm.nih.gov/pubmed/19568437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0006124
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы